All In Biotech

Drug Trial Radar · NCT01221597

Study of AA4500 in the Treatment of Peyronie's Disease

A Phase 3, Double-blind, Randomized, Placebo-controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease

Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 418 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

418

Actual

Start

Sep 2010

Primary completion

Apr 2012

Study completion Apr 2012

Sponsor

Sponsor type
Industry
First posted
Oct 15, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 400 (267 AA4500 and 133 placebo) men will be randomized. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle. Before dosing, subjects will be stratified by degree of penile curvature deformity (ie, 30º to 60º or 61º to 90º) and then randomized into two treatment groups to receive in a 2:1 ratio either AA4500 0.58 mg or placebo. In this study, qualified subjects may receive up to four treatment cycles; each cycle will be separated by a period of 42 days (± 5 days). During each treatment cycle, subjects will receive two injections of study drug with at least 24 hours but not more than 72 hours between injections. After the final injection of each treatment cycle, the investigator or qualified designee will model the penile plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \<15 degrees after the first, second, or third cycle of injections or if further treatment is not clinically indicated, subsequent treatment cycles will not be administered. Following the maximum of four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 169 (± 7 days), 232 (± 7 days), 295 (± 7 days), 365 (± 7 days) (nominal weeks 24, 33, 42 and 52). Subjects randomized to placebo may receive open-label AA4500 treatment after completing this study as part of another protocol.

Conditions

  • Peyronie's Disease

Interventions

  • AA4500Biological

    2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.

  • PlaceboBiological

    2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline in Penile CurvatureTime frame: Baseline and Week 52
  2. Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)Time frame: Baseline and Week 52

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Urology Centers of Alabama, PC

    Homewood, Alabama

  • HOPE Research Institute, LLC

    Phoenix, Arizona

  • Urology Associates Medical Group

    Burbank, California

  • California Professional Research

    Newport Beach, California

  • San Diego Sexual Medicine

    San Diego, California

  • Grove Hill Clinical Research, Grove Hill Medical Center

    New Britain, Connecticut

  • The Urology Center, PC

    New Haven, Connecticut

  • DCT-Celebration, LLC dba Discovery Clinical Trials

    Celebration, Florida

  • Palm Beach Urology Associates

    Wellington, Florida

  • Southeastern Medical Research Institute

    Columbus, Georgia

  • DuPage Medical Group

    Downers Grove, Illinois

  • Urology of Indiana LLC

    Avon, Indiana

  • Chesapeake Urology Research Associates

    Baltimore, Maryland

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Mens Health Boston

    Brookline, Massachusetts

  • Mayo Clinic at Rochester, Dept. of Urology

    Rochester, Minnesota

  • Center for Reproductive Medicine

    Hackensack, New Jersey

  • Division of Urology at Maimonides Medical Center

    Brooklyn, New York

  • Alliance Urology Specialists, PA

    Greensboro, North Carolina

  • Wake Urological Associates

    Raleigh, North Carolina

  • Tristate Urologic Services PSC Inc. dba TUG Research

    Cincinnati, Ohio

  • Urology Health Specialists,LLC

    Bryn Mawr, Pennsylvania

  • Urological Associates of Lancaster

    Lancaster, Pennsylvania

  • Alpha Clinical Research, LLC

    Clarksville, Tennessee

  • Urology Associates of North Texas

    Arlington, Texas

  • Baylor College of Medicine, Department of Urology

    Houston, Texas

  • Salt Lake Research, PLLC

    Salt Lake City, Utah

  • Urology of Virginia - Sentara Medical Group

    Norfolk, Virginia

  • Medical College of Wisconsin, Department of Urology

    Milwaukee, Wisconsin

  • Australian Centre for Sexual Health

    St Leonards, New South Wales, Australia

  • Western Urology

    Westmead, New South Wales, Australia

  • AusTrials

    Kipparing, Queensland, Australia

  • Repatriation General Hospital

    Daws Park, South Australia, Australia

  • Australian Urology Associates Pty Ltd

    Malvern, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.